MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.
Public ClinicalTrials.gov record NCT03611556. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) With or Without Durvalumab in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma
Study identification
- NCT ID
- NCT03611556
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- MedImmune LLC
- Industry
- Enrollment
- 213 participants
Conditions and interventions
Conditions
Interventions
- 5-FU Drug
- Durvalumab Drug
- Folinic acid Drug
- Gemcitabine Drug
- Nab-paclitaxel Drug
- Oleclumab Drug
- Oxaliplatin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 101 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 20, 2018
- Primary completion
- Jul 21, 2022
- Completion
- Jul 21, 2022
- Last update posted
- Oct 2, 2023
2018 – 2022
United States locations
- U.S. sites
- 18
- U.S. states
- 15
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | La Jolla | California | 92093 | — |
| Research Site | Aurora | Colorado | 80045 | — |
| Research Site | Fort Myers | Florida | 33901 | — |
| Research Site | Atlanta | Georgia | 30322 | — |
| Research Site | Boston | Massachusetts | 02114 | — |
| Research Site | Boston | Massachusetts | 02215 | — |
| Research Site | Ann Arbor | Michigan | 48109 | — |
| Research Site | Buffalo | New York | 14263 | — |
| Research Site | Durham | North Carolina | 27710 | — |
| Research Site | Cincinnati | Ohio | 45219 | — |
| Research Site | Columbus | Ohio | 43210 | — |
| Research Site | Philadelphia | Pennsylvania | 19111 | — |
| Research Site | Nashville | Tennessee | 37203 | — |
| Research Site | Dallas | Texas | 75235 | — |
| Research Site | Houston | Texas | 77030 | — |
| Research Site | Charlottesville | Virginia | 22908 | — |
| Research Site | Seattle | Washington | 98109 | — |
| Research Site | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03611556, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 2, 2023 · Synced May 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03611556 live on ClinicalTrials.gov.